Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1

Conditions

Nasopharyngeal Carcinoma 18Esophageal Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Stomach Neoplasms 4Neoplasms 3Colorectal Neoplasms 3Recurrence 2Pancreatic cancer, adult 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Diffuse Intrinsic Pontine Glioma 2Carcinoma 2Adenocarcinoma 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Anal Canal 1Solid Tumors 1Solid Tumor 1Resectable Pancreatic Cancer 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Nasopharyngeal Diseases 1

Interventions

Cisplatin 55Carboplatin 50pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Cetuximab 18Docetaxel 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 13Sorafenib 12Radiation 11130-nm albumin-bound paclitaxel 11Sunitinib 10Platinum 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × nimotuzumab × Clear all
NCT01345084 2025-03-28

NICAP

Eurofarma Laboratorios S.A.

Phase 3 Withdrawn
Head & Neck

Carcinoma, Head and Neck Neoplasms

NCT01301612 2014-07-14

Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Eurofarma Laboratorios S.A.

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡